CA2977960C - Reduction of adipose tissue - Google Patents

Reduction of adipose tissue Download PDF

Info

Publication number
CA2977960C
CA2977960C CA2977960A CA2977960A CA2977960C CA 2977960 C CA2977960 C CA 2977960C CA 2977960 A CA2977960 A CA 2977960A CA 2977960 A CA2977960 A CA 2977960A CA 2977960 C CA2977960 C CA 2977960C
Authority
CA
Canada
Prior art keywords
pharmaceutical formulation
polidocanol
amount
formulation
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2977960A
Other languages
English (en)
French (fr)
Other versions
CA2977960A1 (en
Inventor
John Daniel Dobak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2977960A1 publication Critical patent/CA2977960A1/en
Application granted granted Critical
Publication of CA2977960C publication Critical patent/CA2977960C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CA2977960A 2015-02-27 2016-02-24 Reduction of adipose tissue Active CA2977960C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562121927P 2015-02-27 2015-02-27
US62/121,927 2015-02-27
US201562165716P 2015-05-22 2015-05-22
US62/165,716 2015-05-22
US14/796,686 US9351945B1 (en) 2015-02-27 2015-07-10 Reduction of adipose tissue
US14/796,686 2015-07-10
PCT/US2016/019366 WO2016138136A1 (en) 2015-02-27 2016-02-24 Reduction of adipose tissue

Publications (2)

Publication Number Publication Date
CA2977960A1 CA2977960A1 (en) 2016-09-01
CA2977960C true CA2977960C (en) 2022-11-15

Family

ID=56027678

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2977960A Active CA2977960C (en) 2015-02-27 2016-02-24 Reduction of adipose tissue

Country Status (9)

Country Link
US (6) US9351945B1 (enExample)
EP (2) EP3744330B1 (enExample)
JP (2) JP6566531B2 (enExample)
KR (4) KR20250156844A (enExample)
CN (2) CN110339159B (enExample)
AU (1) AU2016222802B2 (enExample)
CA (1) CA2977960C (enExample)
ES (2) ES2970312T3 (enExample)
WO (1) WO2016138136A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535228B2 (en) 2004-10-06 2013-09-17 Guided Therapy Systems, Llc Method and system for noninvasive face lifts and deep tissue tightening
US10864385B2 (en) 2004-09-24 2020-12-15 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US8444562B2 (en) 2004-10-06 2013-05-21 Guided Therapy Systems, Llc System and method for treating muscle, tendon, ligament and cartilage tissue
US9694212B2 (en) 2004-10-06 2017-07-04 Guided Therapy Systems, Llc Method and system for ultrasound treatment of skin
US8133180B2 (en) 2004-10-06 2012-03-13 Guided Therapy Systems, L.L.C. Method and system for treating cellulite
US8690779B2 (en) 2004-10-06 2014-04-08 Guided Therapy Systems, Llc Noninvasive aesthetic treatment for tightening tissue
US11235179B2 (en) 2004-10-06 2022-02-01 Guided Therapy Systems, Llc Energy based skin gland treatment
US11883688B2 (en) 2004-10-06 2024-01-30 Guided Therapy Systems, Llc Energy based fat reduction
US11207548B2 (en) 2004-10-07 2021-12-28 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US11724133B2 (en) 2004-10-07 2023-08-15 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US12102473B2 (en) 2008-06-06 2024-10-01 Ulthera, Inc. Systems for ultrasound treatment
KR102087909B1 (ko) 2008-06-06 2020-03-12 얼테라, 인크 코스메틱 치료 시스템
EP2382010A4 (en) 2008-12-24 2014-05-14 Guided Therapy Systems Llc METHOD AND SYSTEMS FOR FAT REDUCTION AND / OR TREATMENT OF CELLULITE
US8900181B2 (en) 2009-12-18 2014-12-02 Srgi Holdings, Llc Skin treatment and drug delivery device
US11278309B2 (en) 2010-12-17 2022-03-22 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US10368904B2 (en) 2013-12-06 2019-08-06 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US11612410B2 (en) 2010-12-17 2023-03-28 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US11103275B2 (en) 2010-12-17 2021-08-31 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US10695546B2 (en) 2010-12-17 2020-06-30 Srgi Holdings, Llc Systems, devices and methods for fractional resection, fractional skin grafting, fractional scar reduction and fractional tattoo removal
US10702684B2 (en) 2010-12-17 2020-07-07 Srgi Holdings, Llc Systems, devices and methods for fractional resection, fractional skin grafting, fractional scar reduction and fractional tattoo removal
US11000310B2 (en) 2010-12-17 2021-05-11 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US10736653B2 (en) 2013-12-06 2020-08-11 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US10661063B2 (en) 2010-12-17 2020-05-26 Srgi Holdings, Llc Systems, devices and methods for fractional resection, fractional skin grafting, fractional scar reduction and fractional tattoo removal
CN113648551B (zh) 2013-03-08 2025-03-25 奥赛拉公司 用于多焦点超声治疗的装置和方法
JP6815864B2 (ja) 2013-10-02 2021-01-20 エスアールジーアイ ホールディングス エルエルシーＳｒｇｉ Ｈｏｌｄｉｎｇｓ Ｌｌｃ ピクセルアレイ医療デバイス及び方法
ES2827049T3 (es) 2013-10-02 2021-05-19 Srgi Holdings Llc Dispositivos médicos de conjunto de píxeles
US11937846B2 (en) 2013-12-06 2024-03-26 Srgi Holdings Llc Pixel array medical systems, devices and methods
US11229452B2 (en) 2013-12-06 2022-01-25 Srgi Holdings, Llc Pixel array medical systems, devices and methods
CN106470735B (zh) 2014-04-18 2019-09-20 奥赛拉公司 带式换能器超声治疗
JP6805157B2 (ja) 2015-02-05 2020-12-23 エスアールジーアイ ホールディングス エルエルシーＳｒｇｉ Ｈｏｌｄｉｎｇｓ Ｌｌｃ ピクセルアレイ医療システム、デバイスおよび方法
US9351945B1 (en) * 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
US11751903B2 (en) 2015-08-31 2023-09-12 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US11490952B2 (en) 2015-08-31 2022-11-08 Srgi Holdings, Llc Pixel array medical devices and methods
KR102707101B1 (ko) 2016-01-18 2024-09-13 얼테라, 인크 환형 초음파 어레이가 가요성 인쇄 회로 기판에 지엽적으로 전기적으로 연결된 컴팩트한 초음파 디바이스 및 그 조립 방법
US11564706B2 (en) 2019-10-28 2023-01-31 Srgi Holdings, Llc Pixel array medical systems, devices and methods
EP3251654A1 (de) * 2016-05-30 2017-12-06 Chemische Fabrik Kreussler & Co. Gmbh Nichtionische tenside zur reduktion von fettgewebe
IL301765B2 (en) 2016-08-16 2025-01-01 Ulthera Inc Systems and methods for cosmetic skin treatment using ultrasound
ES2886651T3 (es) * 2016-10-28 2021-12-20 Merz Pharma Gmbh & Co Kgaa Tratamiento cosmético de la celulitis
WO2020086915A2 (en) 2017-05-03 2020-04-30 Srgi Holdings Llc Handed spiral slotted scalpet array
TWI797235B (zh) 2018-01-26 2023-04-01 美商奧賽拉公司 用於多個維度中的同時多聚焦超音治療的系統和方法
US11944849B2 (en) * 2018-02-20 2024-04-02 Ulthera, Inc. Systems and methods for combined cosmetic treatment of cellulite with ultrasound
IT201800006109A1 (it) 2018-06-07 2019-12-07 Polidocanolo per uso come immunomodulatore
US20210000760A1 (en) * 2018-10-16 2021-01-07 Polithera, Inc. Alcohol-based compositions and uses thereof
US11986443B2 (en) * 2018-10-16 2024-05-21 Polithera, Inc. Alcohol-based compositions and uses thereof
EP3713551B1 (en) 2018-10-16 2023-06-07 Polithera, Inc. Alcohol-based compositions and uses thereof
IL321967A (en) 2018-11-30 2025-09-01 Ulthera Inc Systems and methods for increasing the effectiveness of ultrasound therapy
CA3137928A1 (en) 2019-07-15 2021-01-21 Ulthera, Inc. Systems and methods for measuring elasticity with imaging of ultrasound multi-focus shearwaves in multiple dimensions
KR102937196B1 (ko) 2020-07-09 2026-03-09 주식회사 엘지에너지솔루션 통신 시스템 및 방법
EP3973951A1 (en) * 2020-09-23 2022-03-30 Polithera, Inc. Alcohol-based compositions and uses thereof
WO2025101049A1 (ko) * 2023-11-07 2025-05-15 (주)시지바이오 지방분해주사제 조성물
WO2025122498A1 (en) * 2023-12-04 2025-06-12 10Xbio, Llc Reduction of adipose tissue

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267169A (en) * 1978-07-22 1981-05-12 Toko Yakuhin Kogyo Kabushiki Kaisha Novel preparation of clotrimazole
US5164320A (en) * 1990-03-05 1992-11-17 Becton, Dickinson And Company Method for lysing hard liposomes using polyethyleneglycol mono-n-alkyl ethers
ES2114569T3 (es) 1991-10-16 1998-06-01 Richardson Vicks Inc Sistema mejorado de penetracion en la piel para la administracion topica mejorada de farmacos.
KR950702436A (ko) 1992-07-28 1995-07-29 자코부스 코르넬리스 라세르 가교 결합 양이온성 중합체 및 알콜실화 에테르를 함유하는 국소용 약학 조성물(pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether)
ES2068151B1 (es) 1993-06-23 1995-11-16 Cabrera Garrido Juan Microespuma inyectable para esclerosis.
US5681552A (en) 1995-05-23 1997-10-28 The Mennen Company Clear cosmetic stick composition containing a combination of anionic and non-ionic surfactants
ES2317657T3 (es) 1996-09-19 2009-04-16 The Regents Of The University Of Michigan Polimeros que contienen polisacaridos tales como alginatos o alginatos modificados.
JP5062708B2 (ja) * 1998-02-24 2012-10-31 株式会社マンダム 防腐殺菌剤及び人体施用組成物
US7494488B2 (en) 1998-05-28 2009-02-24 Pearl Technology Holdings, Llc Facial tissue strengthening and tightening device and methods
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
CH693625A5 (it) 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
GB9912356D0 (en) 1999-05-26 1999-07-28 Btg Int Ltd Generation of microfoam
GB0028692D0 (en) 2000-11-24 2001-01-10 Btg Int Ltd Generation of therapeutic microform
EP1266682B1 (de) 2001-06-11 2004-01-28 Filtertek B.V. Kombinationsfilter-Anordnung
US20030216364A1 (en) 2001-08-13 2003-11-20 Johnson Keith Arthur Dermatological Formulation
DE10158199A1 (de) 2001-11-27 2003-06-18 Beiersdorf Ag Juckreizstillende kosmetische und dermatologische Zubereitungen
JP4387639B2 (ja) * 2002-07-16 2009-12-16 久光製薬株式会社 経皮吸収製剤
AU2003298747A1 (en) 2002-12-02 2004-06-23 Allergan, Inc. Active agent delivery method
GB0307869D0 (en) 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
GB0321210D0 (en) 2003-09-10 2003-10-08 Btg Int Ltd Apparatus and method for dispensing foam
US20050089555A1 (en) 2003-10-24 2005-04-28 Aventis Pharma Deutschland Gmbh Medicinal targeted local lipolysis
DE10349979B4 (de) 2003-10-24 2006-05-18 Sanofi-Aventis Deutschland Gmbh Medikamentöse gezielte lokale Lipolyse
WO2005065079A2 (en) 2003-11-10 2005-07-21 Angiotech International Ag Medical implants and fibrosis-inducing agents
EP1684718A1 (en) 2003-11-17 2006-08-02 Btg International Limited Methods of preparing a foam comprising a sclerosing agent
US20050143347A1 (en) 2003-12-22 2005-06-30 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of accumulations of fat
JP5032849B2 (ja) 2004-01-14 2012-09-26 ギリアード サイエンシーズ， インコーポレイテッド 薬物送達に有用な脂質ベースの分散物
ES2372499T3 (es) 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
WO2006133876A1 (en) * 2005-06-17 2006-12-21 Dsm Ip Assets B.V. Use of pyrimidine derivatives for cosmetic purposes
DE102005037844A1 (de) 2005-08-04 2007-04-05 Intendis Gmbh Wasserfreies Mehr-Phasen-Gel-System
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
CN100364546C (zh) * 2005-09-16 2008-01-30 陕西天宇制药有限公司 聚桂醇注射液及其制备方法
US20070135343A1 (en) * 2005-11-01 2007-06-14 Wyeth Sodium chloride solution for drug reconstitution or dilution
WO2007062494A1 (en) 2005-11-30 2007-06-07 Generex Pharmaceuticals Inc. Orally absorbed pharmaceutical formulation and method of administration
CN101626759B (zh) * 2006-10-17 2014-08-06 利特拉公司 用于治疗甲状腺眼病的组合物和制剂
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
EP2073794A2 (en) 2006-11-14 2009-07-01 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
GB0623838D0 (en) 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
EP1946746A1 (en) 2007-01-17 2008-07-23 Merz Pharma GmbH & Co. KGaA Particulate aqueous system for the preparation of a formulation for the treatment of adipose diseases
BRPI0806773A2 (pt) 2007-01-17 2011-09-13 Merz Pharma Gmbh & Co Kgaa uso de um tensoativo para o preparo de uma formulação para o tratamento de doenças do tecido adiposo
EP1970051A1 (en) 2007-03-14 2008-09-17 Merz Pharma GmbH & Co.KGaA Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases
DE102007015701A1 (de) * 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
MX2009012273A (es) 2007-05-18 2010-04-09 Tti Ellebeau Inc Dispositivos de suministro transd?rmico que aseguran la liberaci?n mejorada de un principio activo a trav?s de una interfaz biol?gica.
US20080294072A1 (en) 2007-05-24 2008-11-27 Crutchfield Dermatology Mesotherapy with ultrasound
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
US20090202467A1 (en) 2008-02-08 2009-08-13 Bock Richard W Sclerotherapy for varicose veins
KR20090116981A (ko) * 2008-05-08 2009-11-12 (주)와이즈덤레버러토리 석류피 추출물을 유효성분으로 포함하는 면역반응 조절을통한 탈모 방지 및 치료용 조성물
TWM351548U (en) 2008-07-17 2009-02-21 Wistron Corp Oscillating power generator with a ratchet mechanism
CA2741334A1 (en) 2008-10-22 2010-04-29 Allergan, Inc. Clinical assessment scales and methods
KR101725196B1 (ko) 2009-02-25 2017-04-10 스티펠 리서치 오스트레일리아 피티와이 리미티드 국소 폼 조성물
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
BR112012031623B1 (pt) 2010-06-11 2018-04-10 The Procter & Gamble Company Composição para cuidados pessoais e seu uso
US20120016347A1 (en) 2010-07-13 2012-01-19 Shipp John I Seroma Control for Surgical Patients
EP2593093A1 (en) 2010-07-16 2013-05-22 Merz Pharma GmbH & Co. KGaA Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue
US20130331332A1 (en) 2011-03-01 2013-12-12 Merz Pharma Gmbh & Co. Kgaa Composition comprising peroxisome proliferator-activated receptor-gamma
US9241921B2 (en) 2011-05-02 2016-01-26 Pankaj Modi Photosensitizer composition for treating skin disorders
CN102198089A (zh) * 2011-05-19 2011-09-28 陕西天宇制药有限公司 聚桂醇注射液作为治疗内痔药物的应用
DK2785336T3 (da) 2011-11-30 2016-01-11 Merz Pharma Gmbh & Co Kgaa Anvendelse af pegylerede alkoholer til behandling af aktinisk keratose
WO2014164815A2 (en) * 2013-03-12 2014-10-09 Allergan, Inc. Adipose tissue combinations, devices, and uses thereof
CN103191146B (zh) * 2013-04-22 2015-05-13 福建医科大学附属协和医院 一种高效无痛的肿瘤局部消融治疗药物
JP2016520613A (ja) * 2013-05-28 2016-07-14 モメンタ ファーマシューティカルズ インコーポレイテッド 薬学的組成物
US20140356968A1 (en) * 2013-06-04 2014-12-04 Therapeutic Proteins International, LLC Methods for comparing a structure of a first biomolecule and a second biomolecule
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
EP3251654A1 (de) * 2016-05-30 2017-12-06 Chemische Fabrik Kreussler & Co. Gmbh Nichtionische tenside zur reduktion von fettgewebe

Also Published As

Publication number Publication date
ES2819148T3 (es) 2021-04-15
US20160310444A1 (en) 2016-10-27
KR20170139003A (ko) 2017-12-18
CN110339159A (zh) 2019-10-18
KR20230128392A (ko) 2023-09-04
JP2019218353A (ja) 2019-12-26
EP3744330A1 (en) 2020-12-02
JP6920379B2 (ja) 2021-08-18
EP3261646B1 (en) 2020-07-22
US9844520B2 (en) 2017-12-19
KR20200084903A (ko) 2020-07-13
US11065210B2 (en) 2021-07-20
EP3261646A1 (en) 2018-01-03
CN110339159B (zh) 2023-01-17
US20210378984A1 (en) 2021-12-09
AU2016222802A1 (en) 2017-10-12
CA2977960A1 (en) 2016-09-01
US20250073181A1 (en) 2025-03-06
US20200085763A1 (en) 2020-03-19
US20180228741A1 (en) 2018-08-16
KR102266369B1 (ko) 2021-06-16
US12133836B2 (en) 2024-11-05
WO2016138136A1 (en) 2016-09-01
CN107530359B (zh) 2020-02-18
KR20250156844A (ko) 2025-11-03
JP2018506575A (ja) 2018-03-08
AU2016222802B2 (en) 2020-11-05
ES2970312T3 (es) 2024-05-28
EP3261646A4 (en) 2018-11-14
CN107530359A (zh) 2018-01-02
JP6566531B2 (ja) 2019-08-28
US9351945B1 (en) 2016-05-31
US10485767B2 (en) 2019-11-26
EP3744330B1 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
US12133836B2 (en) Reduction of adipose tissue
ES2727269T3 (es) Métodos y composiciones para la reducción de la grasa corporal y adipocitos
CA2761744C (en) Methods for administration and formulations for the treatment of regional adipose tissue
EP1890732A1 (en) Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
KR20140025312A (ko) 지방증 및 윤곽 팽창의 미용적 치료를 위한 선택적인, 친유성, 및 지속성 베타 작용제 단일치료 제형 및 방법
US20180296646A1 (en) Treatment of epithelial layer lesions
JP7124234B2 (ja) フェノルドパムの安定な局所用組成物
HK40014982A (en) Reduction of adipose tissue
US20240074973A1 (en) Pharmaceutical composition for topical administration containing epi-nastine or salt thereof
HK40014982B (en) Reduction of adipose tissue
WO2025122498A1 (en) Reduction of adipose tissue
HK40097614A (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
AU2006200822A1 (en) Treatment of epithelial layer lesions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250217

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250217

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260123

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20260123

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260129

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260218

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260220

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260223